AKTX on Nasdaq
Akari Therapeutics Plc
$8.37 up 1.09 (14.97%)Price as of Oct 15, 2026 at 17:33 UTC
Last updated Oct 16, 2026.
Overview
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Financial statements
Every line of the income statement in the latest annual report, as filed.8
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Research and development | $2.8M | $7.0M |
| General and administrative | $9.3M | $9.7M |
| Impairment loss on other intangible assets | $5.2M | |
| Merger-related expenses | $3.3M | |
| Restructuring and other expenses | $1.7M | |
| Total operating expenses | $17.3M | $21.6M |
| Loss from operations | -$17.3M | -$21.6M |
| Interest income | $1.0K | $8.0K |
| Interest expense | -$949.0K | -$244.0K |
| Gain on settlement of current liabilities | $3.0M | |
| Loss on debt extinguishment | -$3.2M | |
| Change in fair value of warrant liabilities | $775.0K | $2.1M |
| Loss on derivative liability | -$230.0K | |
| Foreign currency exchange gains (losses), net | -$443.0K | $6.0K |
| Other expense, net | -$3.0K | |
| Total other income, net | -$1.0M | $1.9M |
| Net loss before income taxes | -$18.3M | -$19.8M |
| Income tax benefit | $1.0M | |
| Net loss | -$17.3M | -$19.8M |
| Net loss per share - basic | $0.00 | $0.00 |
| Net loss per share - diluted | $0.00 | $0.00 |
| Weighted-average number of Ordinary Shares used in computing net loss per share - basic | 67.3B shares | 23.9B shares |
| Weighted-average number of Ordinary Shares used in computing net loss per share - diluted | 67.3B shares | 23.9B shares |
| Foreign currency translation adjustment | -$44.0K | $302.0K |
| Total other comprehensive income, net of tax | -$44.0K | $302.0K |
| Total comprehensive loss | -$17.3M | -$19.5M |
Every line of the balance sheet in the latest annual report, as filed.8
| Period ending | 2025-12-31 | 2025-11-30 | 2024-12-31 |
|---|---|---|---|
| Cash | $5.2M | $2.6M | |
| Restricted cash | $60.0K | $60.0K | |
| Prepaid expenses | $185.0K | $92.0K | |
| Other current assets | $14.0K | $201.0K | |
| Total current assets | $5.5M | $3.0M | |
| Goodwill | $8.4M | $8.4M | |
| Other intangible assets | $34.0M | $39.2M | |
| Total assets | $47.9M | $50.6M | |
| Accounts payable | $8.8M | $12.4M | |
| Accrued expenses | $2.3M | $3.1M | |
| Convertible notes, net | $673.0K | $700.0K | |
| Convertible notes, related party | $250.0K | ||
| Notes payable, net | $81.0K | $659.0K | |
| Notes payable, related party | $1.7M | ||
| Warrant liabilities | $61.0K | $1.0M | |
| Other current liabilities | $424.0K | $94.0K | |
| Total current liabilities | $12.4M | $19.9M | |
| Derivative liability | $230.0K | ||
| Other non-current liabilities | $31.0K | $383.0K | |
| Deferred tax liability | $7.0M | $8.0M | |
| Total liabilities | $19.6M | $28.3M | |
| Share capital of $0.000000005 par value Authorized: 761,963,201,733 and 245,035,791,523 ordinary shares at December 31, 2025 and December 31, 2024, respectively; issued and outstanding: 90,536,879,533 and 53,186,919,523 ordinary shares at December 31, 2025 and December 31, 2024, respectively | $5.3M | ||
| Additional paid-in capital | $234.3M | $212.7M | |
| Capital redemption reserve | $59.3M | $52.2M | |
| Accumulated other comprehensive loss | -$782.0K | -$738.0K | |
| Accumulated deficit | -$264.6M | -$247.3M | |
| Total shareholders equity | $28.3M | $22.2M | |
| Total liabilities and shareholders equity | $47.9M | $50.6M | |
| Ordinary shares, par value | $0.00 | $0.00 | $0.00 |
| Ordinary shares, shares authorized | 762.0B shares | 762.0B shares | 245.0B shares |
| Ordinary shares, shares issued | 90.5B shares | 53.2B shares | |
| Ordinary shares, shares outstanding | 90.5B shares | 53.2B shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow in the latest annual report, as filed.8
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Net loss | -$17.3M | -$19.8M |
| Depreciation and amortization | $14.0K | |
| Stock-based compensation | $2.9M | $2.2M |
| Issuance of shares for services | $27.0K | $271.0K |
| Accretion of debt issuance costs | $589.0K | |
| Gain on settlement of current liabilities | -$3.0M | |
| Loss on debt extinguishment | $3.2M | |
| Change in fair value of warrant liabilities | -$775.0K | -$2.1M |
| Impairment loss on other intangible assets | $5.2M | |
| Loss on derivative liability | $230.0K | |
| Deferred income tax benefit | -$1.1M | |
| Unrealized foreign currency exchange losses (gains) | -$99.0K | $255.0K |
| Prepaid expenses and other current assets | $594.0K | $1.3M |
| Accounts payable and accrued expenses | -$998.0K | $5.2M |
| Net cash used in operating activities | -$10.6M | -$12.6M |
| Cash acquired in Peak Bio Acquisition | $382.0K | |
| Net cash provided by investing activities | $382.0K | |
| Proceeds from issuance of shares, net of issuance costs | $10.7M | $11.8M |
| Proceeds from issuance of warrants | $1.0M | |
| Proceeds from issuance of notes payable | $2.1M | |
| Proceeds from issuance of convertible notes | $1.0M | |
| Repayment of notes payable and convertible notes | -$553.0K | -$750.0K |
| Proceeds from issuance of restricted shares | $26.0K | |
| Proceeds from employee vesting of restricted shares | $33.0K | $2.0K |
| Proceeds from pre-funded warrants | $330.0K | |
| Payments on seller-financed purchases | -$499.0K | -$1.1M |
| Net cash provided by financing activities | $13.2M | $11.0M |
| Effect of exchange rates on cash | $1.0K | -$4.0K |
| Net change in cash | $2.6M | -$1.2M |
| Financing costs in accounts payable and accrued expenses | $348.0K | |
| Seller-financed purchases | $499.0K | $1.1M |
| Issuance of share capital for settlement of convertible notes, related party | $309.0K | |
| Issuance of share capital for settlement of related party debt | $1.0M | |
| Issuance of share capital for payments in kind | $595.0K | |
| Modification of warrants in connection with issuance of notes payable | $2.6M | |
| Modification of warrants in connection with amendment of convertible notes | $192.0K | |
| Issuance of warrants in connection with note exchange and cancellation | $4.0M | |
| Payroll taxes on stock-based compensation in accrued expenses | $193.0K | |
| Issuance of ordinary shares for Peak Bio Acquisition | $28.1M | |
| Warrants assumed in connection with Peak Bio Acquisition | $1.8M | |
| Cash paid for interest | $101.0K | $143.0K |
Former names
Recent filings
- Oct 14, 20263
- Oct 14, 20264
- Oct 1, 20268-K
- Oct 1, 20264
- Oct 1, 2026DEF 14A
- Aug 19, 20264
- Aug 13, 202610-Q
- Aug 13, 20268-K
- Aug 12, 2026SCHEDULE 13G
- Aug 7, 2026SCHEDULE 13G
- Aug 5, 20264
- Jul 17, 20264
- Jul 13, 2026EFFECT
- Jul 10, 2026S-3/A
- Jul 8, 2026S-3/A
Every filing from the last three years, summarized. The full record is on SEC EDGAR.1
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2Yahoo FinanceAKTX quote
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12